SMT202100089T1 - Pirrol ammidi come inibitori delle integrine alfa v - Google Patents

Pirrol ammidi come inibitori delle integrine alfa v

Info

Publication number
SMT202100089T1
SMT202100089T1 SM20210089T SMT202100089T SMT202100089T1 SM T202100089 T1 SMT202100089 T1 SM T202100089T1 SM 20210089 T SM20210089 T SM 20210089T SM T202100089 T SMT202100089 T SM T202100089T SM T202100089 T1 SMT202100089 T1 SM T202100089T1
Authority
SM
San Marino
Prior art keywords
alpha
integrin inhibitors
pyrrole amides
pyrrole
amides
Prior art date
Application number
SM20210089T
Other languages
English (en)
Italian (it)
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT202100089T1 publication Critical patent/SMT202100089T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
SM20210089T 2016-11-08 2017-11-07 Pirrol ammidi come inibitori delle integrine alfa v SMT202100089T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418833P 2016-11-08 2016-11-08
EP17801236.5A EP3538528B1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors
PCT/US2017/060392 WO2018089360A1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
SMT202100089T1 true SMT202100089T1 (it) 2021-03-15

Family

ID=60409438

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210089T SMT202100089T1 (it) 2016-11-08 2017-11-07 Pirrol ammidi come inibitori delle integrine alfa v

Country Status (23)

Country Link
US (1) US10717736B2 (enExample)
EP (1) EP3538528B1 (enExample)
JP (1) JP7220653B2 (enExample)
KR (1) KR102515507B1 (enExample)
CN (1) CN110139864B (enExample)
AU (1) AU2017359030A1 (enExample)
BR (1) BR112019009293A2 (enExample)
CA (1) CA3042693A1 (enExample)
CY (1) CY1123893T1 (enExample)
DK (1) DK3538528T3 (enExample)
EA (1) EA201991124A1 (enExample)
ES (1) ES2852351T3 (enExample)
HR (1) HRP20210228T1 (enExample)
HU (1) HUE053620T2 (enExample)
IL (1) IL266469A (enExample)
LT (1) LT3538528T (enExample)
MX (1) MX377293B (enExample)
PL (1) PL3538528T3 (enExample)
PT (1) PT3538528T (enExample)
RS (1) RS61453B1 (enExample)
SI (1) SI3538528T1 (enExample)
SM (1) SMT202100089T1 (enExample)
WO (1) WO2018089360A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
TW201819378A (zh) * 2016-11-08 2018-06-01 美商必治妥美雅史谷比公司 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物
BR112019012515A2 (pt) 2016-12-29 2019-11-19 Saint Louis University antagonistas de integrina
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
WO2020047208A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
US20240208968A1 (en) * 2021-03-10 2024-06-27 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
EP1049693A1 (en) * 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
IL138677A0 (en) 1998-04-10 2001-10-31 Searle & Co Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
JP2002522540A (ja) 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
DE19939981A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
PL355011A1 (en) * 1999-11-08 2004-03-22 Merck & Co, Inc. Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
BRPI0414927A (pt) 2003-10-01 2006-11-07 Merck Patent Ges Mit Beschaenk antagonistas de integrina alfavbeta3 e alfavbeta6 como agentes antifibróticos
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
WO2007141473A1 (en) 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
EP2526095A1 (en) * 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
NZ603789A (en) 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
DK2953948T3 (en) * 2013-02-07 2017-12-18 Scifluor Life Sciences Inc FLUORINATED INTEGRIN ANTAGONISTS
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN114805342A (zh) 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
EP3268369A4 (en) 2015-03-10 2018-08-08 The Regents of The University of California Anti-alphavbeta1 integrin inhibitors and methods of use

Also Published As

Publication number Publication date
CN110139864B (zh) 2022-08-23
RS61453B1 (sr) 2021-03-31
PT3538528T (pt) 2021-02-16
KR102515507B1 (ko) 2023-03-28
HRP20210228T1 (hr) 2021-03-19
US10717736B2 (en) 2020-07-21
MX377293B (es) 2025-03-07
AU2017359030A1 (en) 2019-06-20
KR20190076031A (ko) 2019-07-01
CN110139864A (zh) 2019-08-16
IL266469A (en) 2019-07-31
CY1123893T1 (el) 2022-05-27
JP7220653B2 (ja) 2023-02-10
LT3538528T (lt) 2021-03-10
WO2018089360A1 (en) 2018-05-17
JP2020500182A (ja) 2020-01-09
MX2019005233A (es) 2019-08-12
US20190256512A1 (en) 2019-08-22
CA3042693A1 (en) 2018-05-17
EP3538528A1 (en) 2019-09-18
ES2852351T3 (es) 2021-09-13
DK3538528T3 (da) 2021-02-15
BR112019009293A2 (pt) 2019-07-30
PL3538528T3 (pl) 2021-05-31
SI3538528T1 (sl) 2021-03-31
HUE053620T2 (hu) 2021-07-28
EA201991124A1 (ru) 2019-10-31
EP3538528B1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
IL266469A (en) Pyrrol-amides as alpha-v-integrin inhibitors
ZA201905811B (en) Novel inhibitors
IL266470A (en) Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
IL258180B (en) Heterocyclic compounds and their uses
IL272649A (en) AHR inhibitors and their uses
GB201605126D0 (en) Inhibitors and their uses
GB201708652D0 (en) Novel compounds and uses
IL266465A (en) Azole amides and amines as alpha five integrin inhibitors
IL246987A0 (en) Heteroaryl amides, preparations containing it and their uses
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
ZA201907136B (en) Ip6k inhibitors
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
IL275375A (en) Pyrrolidine amides II are converted
IL275374A (en) Pyrrolidine amides I are converted
IL254916B (en) Inhibitors and their uses
IL262400A (en) Erbb inhibitors and uses thereof
IL251077A0 (en) Integrin inhibitors and their use
GB201612860D0 (en) Inhibitors
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
PL3209743T3 (pl) Zastosowanie foliowych materiałów licowych do polimerowego opakowania
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL251078A0 (en) Integrin inhibitors and their use
IL261644A (en) Oxalyl derivatives and their use as cyclophilin inhibitors
GB201721465D0 (en) Inhibitors